Skip to main content

Table 6 Loss of joint space width and of cartilage volume at 36 months in treatment groups in patients with meniscal extrusion

From: Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial

 

SrRan 1 g/day

SrRan 2 g/day

Placebo

P -value

Placebo versus

SrRan 1 g/day

Placebo versus

SrRan 2 g/day

n = 19

n = 15

n = 26

P -value

P -value

Joint space width loss

      

  mm

-0.46 ± 0.45

-0.41 ± 0.42

-0.76 ± 0.67

0.085*

  

  %

-18.54 ± 19.69

-14.67 ± 15.69

-23.24 ± 19.23

0.228*

  

MRI (%)

      

Global knee

-7.66 ± 2.10

-6.67 ± 2.56

-8.02 ± 3.28

0.351*

  

  Femur

-7.70 ± 2.66

-6.98 ± 4.26

-7.28 ± 2.91

0.809*

  

  Plateau

-7.61 ± 3.79

-5.74 ± 3.54

-10.01 ± 5.79

0.003*

0.070**

0.007**

Medial compartment

-10.29 ± 3.68

-9.14 ± 3.27

-10.40 ± 4.23

0.119*

  

  Medial femur

-11.17 ± 4.25

-10.72 ± 5.36

-10.89 ± 3.19

0.290*

  

  Medial plateau

-8.13 ± 5.98

-4.90 ± 5.19

-9.07 ± 8.74

0.048*

0.708**

0.081**

  1. Results for cartilage volume loss are percentage (%) of change expressed as mean ± SD. *P-values assessed using the Kruskal-Wallis test; P-values assessed using the **Mann-Whitney test with Bonferroni adjustment. Statistically significant P-values are in bold. SrRan, strontium ranelate; n, number of participants; MRI, magnetic resonance imaging.